Generics· August 18, 2026 · 14 min read
Generic Wakix Approved but Cannot Launch Until 2030: The Orange Book Fence
By Ran Chen#Orange Book#Generics#Generic Entry
Topic
Generic Entry
ANDA approvals, authorized generics, generic launch sequencing, patent expiry, and formulary shifts after generic entry.
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Specialty· August 9, 2026 · 17 min read
Alopecia Areata Treatment Access (2026): Litfulo, Leqselvi, and Olumiant
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Generics· July 15, 2026 · 29 min read
2026–2027 Generic Launch Scorecard: Which Patent Cliffs Are Worth Filing
By Ran Chen#Orange Book#Generic Entry#ANDA Approval
Pricing & Access· July 15, 2026 · 19 min read
IPF Access Landscape 2026: Jascayd, Ofev Generic entry, and Pirfenidone Pricing
Policy· July 15, 2026 · 22 min read
The Post-CREATES REMS Moat Map: Safety Programs Shielding Brands After the Fix
By Ran Chen#REMS#Biosimilars#Generic Entry
Manufacturing· July 15, 2026 · 23 min read
Sterile-Injectable Shortage Ledger: Capacity, Not Another ANDA, Is the Opening
Pricing & Access· July 8, 2026 · 22 min read
Gilead Sciences Portfolio Dossier: The Biktarvy Cliff, Yeztugo PrEP, and an Oncology Reset
By Ran Chen#HIV PrEP#Generic Entry#Drug Pricing
Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor